Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ultragenyx Pharmaceutical (RARE) Other Gross PP&E Adjustments (2016 - 2025)

Ultragenyx Pharmaceutical has reported Other Gross PP&E Adjustments over the past 11 years, most recently at $380.0 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 0.53% to $380.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $380.0 million through Dec 2025, up 0.53% year-over-year, with the annual reading at $380.0 million for FY2025, 0.53% up from the prior year.
  • Other Gross PP&E Adjustments was $380.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $378.0 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $380.0 million in Q4 2025 and troughed at -$38.6 million in Q2 2021.
  • The 5-year median for Other Gross PP&E Adjustments is -$24.7 million (2023), against an average of $93.6 million.
  • The largest YoY upside for Other Gross PP&E Adjustments was 122.14% in 2021 against a maximum downside of 7.49% in 2021.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $156.3 million in 2021, then soared by 90.05% to $297.1 million in 2022, then grew by 25.85% to $374.0 million in 2023, then increased by 1.08% to $378.0 million in 2024, then rose by 0.53% to $380.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Gross PP&E Adjustments are $380.0 million (Q4 2025), $378.0 million (Q4 2024), and $374.0 million (Q4 2023).